Recruiting
Phase 1
Phase 2

NX-5948 & Venetoclax, Rituximab, Obinutuzumab

Sponsor:

Nurix Therapeutics, Inc.

Code:

NCT07520006

Conditions

B-cell Lymphoma

Chronic Lymphocytic Leukemia

Small Lymphocytic Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

NX-5948

venetoclax

rituximab

obinutuzumab

Study Details

Brief summary:

The study will evaluate NX-5948 (bexobrutideg) in combination with venetoclax with or without an anti-CD20 antibody (rituximab or obinutuzumab) in second-line or higher (2L+) relapsed/refractory (R/R) or first-line (1L) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Conditions

B-cell Lymphoma

Chronic Lymphocytic Leukemia

Small Lymphocytic Lymphoma

Study ID

NCT07520006

Start date

Sep 30, 2026

Status verified date

Oct, 2026

Completion date

May, 2033

Anticipated

Primary completion date

May, 2033

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Key Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
  • Adequate organ and bone marrow function
  • Measurable disease by computed tomography (CT) per iwCLL
  • For R/R CLL/SLL, prior therapy must include treatment with a Bruton tyrosine kinase inhibitor (BTKi)
  • For 1L CLL/SLL, confirmed previously untreated CLL/SLL with a clinical indication for systemic treatment that meets iwCLL criteria
  • Must sign an informed consent form indicating understanding of the study purpose and procedures and willingness to participate

Key Exclusion Criteria:

  • Known or suspected prolymphocytic leukemia or Richter's transformation at any time preceding enrollment
  • Investigational agent or anticancer therapy within 5 half-lives or 14 days (whichever is shorter) prior to planned start of study treatment
  • Radiotherapy within 2 weeks of the first dose of study drug except for focal palliative radiation
  • Use of systemic corticosteroids (>20 mg/day prednisone or equivalent) within the 7 days prior to initiation of study treatment excepting those used as prophylaxis for radiodiagnostic contrast
  • Previously treated with a BTK degrader
  • Previously treated with a BCL-2 inhibitor (BCL-2i) unless eligible for retreatment
  • Known central nervous system (CNS) lymphoma or leukemia
  • Myocardial infarction, unstable angina, unstable symptomatic ischemic heart disease, placement of a coronary arterial stent, or any other significant cardiac condition within 6 months of planned start of study treatment
  • Thromboembolic events, stroke, or intracranial hemorrhage within 6 months of planned start of study treatment

Note: Other Inclusion/Exclusion criteria may apply as defined in the protocol.

Study Design

Enrollment

150 participants

Anticipated

Allocation

Non randomized

Intervention Model

Sequential

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: NX-5948 + venetoclax

experimental: NX-5948 + venetoclax + rituximab

experimental: NX-5948 + venetoclax + obinutuzumab

Interventions

NX-5948

Administered orally once daily as a capsule

venetoclax

Administered orally once daily as a tablet per prescribing information

rituximab

Administered as an intravenous (IV) infusion per prescribing information

obinutuzumab

Administered as an IV infusion per prescribing information

Primary outcome measure

  • Number of participants with treatment-emergent adverse events [ Time Frame: Up to approximately 7 years ]

Central Contacts and Locations

Central contacts

Additional Site Contact Information

415-417-3418clinicaltrials@nurixtx.com

Locations

Rocky Mountain Cancer Centers

Recruiting

Aurora, Colorado, United States, 80012

Oncology Associates of Oregon

Recruiting

Eugene, Oregon, United States, 97401

UPMC Hillman Cancer Center

Recruiting

Pittsburgh, Pennsylvania, United States, 15232

SCRI Oncology Partners

Recruiting

Nashville, Tennessee, United States, 37203

Texas Oncology - Northeast

Recruiting

Tyler, Texas, United States, 75702

More Information

Sponsor

Nurix Therapeutics, Inc.

Last update posted

Oct 22, 2026

Last verified

Oct, 2026

Keywords

  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)
  • Degrader
  • B-cell malignancy
  • BTKi
  • Bexobrutideg
  • Venetoclax
  • Obinutuzumab
  • Rituximab

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-23. This information was provided to ClinicalTrials.gov by Nurix Therapeutics, Inc. on 2026-10-22. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.